
    
      TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term
      safety and efficacy of ublituximab in subjects with Relapsing Multiple Sclerosis. Subjects
      who complete the 96-week, double-blind treatment period of TG1101-RMS301 or TG1101-RMS302 are
      eligible for participation in this Open Label Extension (OLE) study.
    
  